Narrow search
Showing 1 - 10 of 38,611
Cover Image
Human resource management for learning through knowledge exploitation and knowledge exploration : pharmaceuticals in Mexico
Santiago Rodriguez, Fernando; Alcorta, Ludovico - In: Structural change and economic dynamics : SC+ED 23 (2012) 4, pp. 530-546
Persistent link: https://www.econbiz.de/10009687474
Cover Image
Investments in Pharmaceuticals Before and After TRIPS
Kyle, Margaret K.; McGahan, Anita M. - In: The Review of Economics and Statistics 94 (2012) 4, pp. 1157-1172
The TRIPS Agreement, which specifies minimum levels of intellectual property protection for countries in the WTO, has increased levels of patent protection around the world. Using variation across countries in the timing of patent laws and the severity of disease, we test the hypothesis that...
Persistent link: https://www.econbiz.de/10011010008
Cover Image
Industrial and organizational mutations in the medical and pharmaceutical sectors impulsed by open innovation during the pandemic
Adatto, Laurent; Aouinait, Camille; Son Thi Kim Le; … - In: Proceedings of the ENTRENOVA - ENTerprise REsearch … 8 (2022) 1, pp. 421-434
The Covid-19 pandemic tragically emphasized severe failures of health systems. In particular, the saturation of hospital infrastructures and the lack of medical devices is crucial for respiratory ventilators. The medical and pharmaceutical sectors had to find urgently new ways to innovate...
Persistent link: https://www.econbiz.de/10014308369
Cover Image
R&D offshoring and clustering dynamics in pharmaceuticals and biotechnology: key features and insights from the Chinese case
Hamdouch, Abdelillah; He, Feng - In: Journal of Innovation Economics n° 4 (2009) 2, pp. 95-117
innovation networks and enterprise?s embeddedness. Above, especially in pharmaceuticals and biotechnology, these two …
Persistent link: https://www.econbiz.de/10008501948
Cover Image
Setting the 'right' goal: Post M&A innovation performance and goal orientation
In: Verslas: Teorija ir praktika / Business: Theory and Practice 21 (2020) 2, pp. 555-565
Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes....
Persistent link: https://www.econbiz.de/10012703623
Cover Image
Innovation crisis in the pharmaceutical industry? A survey
Laermann-Nguyen, Ute; Backfisch, Martin - In: SN Business & Economics 1 (2021) 12
In the literature, it is widely discussed whether the pharmaceutical industry is going through an innovation crisis. Unfortunately, no comprehensive review exists to date that outlines the main empirical findings. In this paper, we provide an extensive survey on what is currently known about the...
Persistent link: https://www.econbiz.de/10014501658
Cover Image
Setting the "right" goal : post M&A innovation performance and goal orientation
Doan Thu Trang - In: Verslas : teorija ir praktika : Vilniaus Gedimino … 21 (2020) 2, pp. 555-565
Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes....
Persistent link: https://www.econbiz.de/10012502063
Cover Image
The impact of public basic research on industrial innovation: Evidence from the pharmaceutical industry
Toole, Andrew A. - In: Research Policy 41 (2012) 1, pp. 1-12
While most economists believe that public scientific research fuels industry innovation and economic growth, systematic evidence supporting this relationship is surprisingly limited. In a recent study, Acemoglu and Linn (2004) identified market size as a significant driver of drug innovation in...
Persistent link: https://www.econbiz.de/10010572691
Cover Image
The determinants of pharmaceutical research and development expenditures
Grabowski, Henry; Vernon, John - In: Journal of Evolutionary Economics 10 (2000) 1, pp. 201-215
Since the late 1970s, pharmaceutical R&D has grown at a rapid rate relative to sales and other variables. In this paper, we examine the determinants of pharmaceutical R&D using a pooled data sample of 11 major drug firms over the period 1974 to 1994. We find that expected returns and cash flows...
Persistent link: https://www.econbiz.de/10005622488
Cover Image
The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003-2013
Lichtenberg, Frank R. - In: Latin American economic review : LAER ; official … 26 (2017), pp. 1-22
I assess the impact that pharmaceutical innovation had on cancer mortality in Mexico during the period 2003–2013, by … the standards of the World Health Organization, new cancer drugs have been very cost-effective in Mexico. The contribution …. Only half as many new cancer drugs were launched in Mexico during 2010–2014 as were launched in the US. In addition, when …
Persistent link: https://www.econbiz.de/10011885726